Literature DB >> 22193242

Should we really consider Gleason 6 prostate cancer?

J Curtis Nickel1, Mark Speakman.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 22193242     DOI： 10.1111/j.1464-410X.2011.10854.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  10 in total

1.  Gleason score 6 adenocarcinoma: should it be labeled as cancer?

Authors:  H Ballentine Carter; Alan W Partin; Patrick C Walsh; Bruce J Trock; Robert W Veltri; William G Nelson; Donald S Coffey; Eric A Singer; Jonathan I Epstein
Journal:  J Clin Oncol       Date:  2012-10-01       Impact factor: 44.544

Review 2.  Does true Gleason pattern 3 merit its cancer descriptor?

Authors:  Saiful Miah; Hashim U Ahmed; Alex Freeman; Mark Emberton
Journal:  Nat Rev Urol       Date:  2016-08-17       Impact factor: 14.432

Review 3.  Active surveillance for prostate cancer: overview and update.

Authors:  Laurence Klotz
Journal:  Curr Treat Options Oncol       Date:  2013-03

4.  African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Authors:  Kosj Yamoah; Curtiland Deville; Neha Vapiwala; Elaine Spangler; Charnita M Zeigler-Johnson; Bruce Malkowicz; David I Lee; Michael Kattan; Adam P Dicker; Timothy R Rebbeck
Journal:  Urol Oncol       Date:  2014-10-07       Impact factor: 3.498

5.  Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer.

Authors:  Robert J Rounbehler; Anders E Berglund; Travis Gerke; Mandeep M Takhar; Shivanshu Awasthi; Weimin Li; Elai Davicioni; Nicholas G Erho; Ashley E Ross; Edward M Schaeffer; Eric A Klein; R Jeffrey Karnes; Robert B Jenkins; John L Cleveland; Jong Y Park; Kosj Yamoah
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-14       Impact factor: 4.254

Review 6.  Should Gleason 6 be labeled as cancer?

Authors:  Ibrahim Kulac; Michael C Haffner; Srinivasan Yegnasubramanian; Jonathan I Epstein; Angelo M De Marzo
Journal:  Curr Opin Urol       Date:  2015-05       Impact factor: 2.309

Review 7.  The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer.

Authors:  Ola Bratt; Stefan Carlsson; Erik Holmberg; Lars Holmberg; Eva Johansson; Andreas Josefsson; Annika Nilsson; Maria Nyberg; David Robinsson; Jonas Sandberg; Dag Sandblom; Pär Stattin
Journal:  Scand J Urol       Date:  2013-07-24       Impact factor: 1.612

8.  Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize?

Authors:  Rodolfo Montironi; Marina Scarpelli; Roberta Mazzucchelli; Antonio Lopez-Beltran; Matteo Santoni; Alberto Briganti; Francesco Montorsi; Liang Cheng
Journal:  Diagn Pathol       Date:  2014-10-18       Impact factor: 2.644

9.  A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study.

Authors:  L Dickinson; H U Ahmed; A P Kirkham; C Allen; A Freeman; J Barber; R G Hindley; T Leslie; C Ogden; R Persad; M H Winkler; M Emberton
Journal:  Contemp Clin Trials       Date:  2013-06-14       Impact factor: 2.261

10.  How Much Reliable Is the Current Belief on Grade Group 1 Prostate Cancer?

Authors:  Mun Su Chung; Yeong Jin Choi; Young Sub Lee; Byung Il Yoon; U-Syn Ha
Journal:  Pathol Oncol Res       Date:  2021-04-13       Impact factor: 3.201
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.